Navigation Links
The Leukemia & Lymphoma Society Receives More Than $36,000 From Regence

Joining not only helped Regence members take charge of their

health but also contributed to the community

PORTLAND, Ore., March 19 /PRNewswire/ -- As part of a fourth-quarter of 2007 enrollment campaign on its customer-focused Web site, Regence recently donated $36,240 to the The Leukemia & Lymphoma Society (LLS).

The company donated $1 for every member who registered on in the final three months of 2007. is designed to advise members on health care and lifestyle options, navigate them through the health care system and reward those who make healthy choices.

"We believe in giving back to the communities in which we live and work," said Will McKinney, Vice President of Consumer Directed Health Systems for Regence. "And because we've maintained a meaningful partnership with The Leukemia & Lymphoma Society, we thought this was another great way to contribute to them."

The more than 36,000 registrants in the last three months of 2007 was a 20 percent increase over the same three-month period in 2006.

In the fourth quarter the last two years, Regence has donated more than $70,000 to charity on behalf of members who have registered on

"LLS is extremely grateful to Regence for setting up this program," said Sarah Varner, executive director, Oregon & SW Washington Chapter of The Leukemia & Lymphoma Society. "Regence's generous donation will help give hope to the many thousands of patients and their families who are battling blood cancers."

With, members can find all their health-related resources in one place. They can check their claims; get fitness and nutrition tips; learn about medical conditions, medications and formulary information; search for doctors; and research cost and care options. They can even earn Regence Rewards points-redeemable for gift certificates at dozens of restaurants, retailers, movie theaters and more-just for actively taking care of their health.

About Regence

Created in 1995, Regence is the largest health insurer in the Pacific Northwest/Mountain State region. It includes Regence BlueShield of Idaho, Regence BlueCross BlueShield of Oregon, Regence BlueCross BlueShield of Utah and Regence BlueShield (in Washington). Through these plans, Regence provides health, life, vision, dental and long-term care insurance to nearly three million members. Regence plans are not-for-profit, independent licensees of the Blue Cross and Blue Shield Association. More than one in three Americans have coverage from the Blues. For more information, visit

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit or call the LLS Information Resource Center (IRC), a call center staffed by master's level oncology social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET

SOURCE Regence
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
(Date:11/30/2015)... Viejo, CA (PRWEB) , ... November 30, 2015 , ... ... Cut Pro X . Choose from scrolling web-styled transitions to wipes with blur ... colors, transition direction and more. Seamlessly transition from one clip to the next ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and Attendance/Workforce Management cloud-based solutions, announced today that it has renewed the ... the Application Development, demonstrating a “best-in-class” ability and commitment to meet Microsoft’s ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... to announce their strategic partnership at the Radiological Society of North America ... and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce their strategic partnership at the Radiological Society of North America (RSNA) ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology: